Want to see SE:CANTA full AI Analyst Report?
Top Page
Cantargia AB
(CANTA)
Select Model
Select Model
Rating:65Neutral
Price Target:
kr1.50
▼(-63.14% Downside)
Action:Downgraded
Date:10/01/26
The score is primarily supported by strong recent financial performance (high margins, strong free cash flow, and a debt-free balance sheet). However, the technical picture is materially bearish (below all key moving averages with negative MACD), and the multi-year history of zero revenue and losses raises uncertainty about the sustainability of the low P/E valuation.
Positive Factors
Debt-free balance sheet
A debt-free structure reduces fixed financial obligations and refinancing exposure, giving Cantargia greater flexibility while clinical programs develop. Positive equity and substantial assets provide a stronger buffer against operating volatility than a highly leveraged biotechnology company would have.
Negative Factors
Highly volatile earnings history
The sharp contrast between several loss-making years and the latest profitable period makes the current earnings base difficult to treat as established. Such volatility can complicate planning, weaken confidence in recurring profitability, and make future cash generation dependent on individual transactions.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free structure reduces fixed financial obligations and refinancing exposure, giving Cantargia greater flexibility while clinical programs develop. Positive equity and substantial assets provide a stronger buffer against operating volatility than a highly leveraged biotechnology company would have.
Read all positive factors
Cantargia AB (CANTA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr390.21M
Dividend YieldN/A
Average Volume (3M)1.70M
Price to Earnings (P/E)2.0
Beta (1Y)0.81
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.68
Shares Outstanding281,944,980
10 Day Avg. Volume1,037,950
30 Day Avg. Volume1,702,862
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr12.00Price Target Upside194.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.77
Revenue Forecast (FY)kr1.05M
Cantargia AB Business Overview & Revenue Model
Company Description
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to t...
How the Company Makes Money
Cantargia primarily makes money through external financing and partnering rather than commercial product sales, as its key assets are (or have been) in clinical development. The main expected/actual revenue sources are: (1) Collaboration and licen...
Cantargia AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
85
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 317.31M | 316.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 316.06M | 313.43M | -3.44M | -3.45M | -3.69M | -3.45M |
| EBITDA | 166.85M | 154.37M | -165.03M | -284.31M | -368.12M | -363.06M |
| Net Income | 167.38M | 146.97M | -161.65M | -280.03M | -371.81M | -366.50M |
Balance Sheet | ||||||
| Total Assets | 307.69M | 296.66M | 170.43M | 223.71M | 474.80M | 600.24M |
| Cash, Cash Equivalents and Short-Term Investments | 221.96M | 281.82M | 33.04M | 194.75M | 426.67M | 559.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 43.89M | 30.78M | 54.12M | 54.97M | 85.11M | 67.50M |
| Stockholders Equity | 263.80M | 265.88M | 116.30M | 168.74M | 389.68M | 532.75M |
Cash Flow | ||||||
| Free Cash Flow | 164.72M | 149.66M | -162.75M | -286.66M | -366.00M | -346.83M |
| Operating Cash Flow | 164.78M | 150.13M | -162.75M | -286.66M | -358.92M | -346.44M |
| Investing Cash Flow | -12.06M | -472.00K | 55.00M | 182.09M | 67.88M | -102.43M |
| Financing Cash Flow | -25.46M | 103.86M | -1.07M | 54.68M | 223.93M | 3.00K |
Cantargia AB Technical Analysis
Neutral
4.07
Price Trends
1.58
Negative
1.78
Negative
3.01
Negative
Market Momentum
-0.06
Negative
44.65
Neutral
62.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CANTA, the sentiment is Neutral. The current price of 4.07 is above the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.58, and above the 200-day MA of 3.01, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.65 is Neutral, neither overbought nor oversold. The STOCH value of 62.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CANTA.
Cantargia AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr390.21M | 2.04 | 63.09% | ― | ― | ― | |
52 Neutral | kr364.08M | -5.68 | -54.41% | ― | ― | 32.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr186.86M | -7.92 | -56.09% | ― | ― | 14.10% | |
47 Neutral | kr728.99M | -2.17 | ― | ― | 87.23% | 35.27% | |
43 Neutral | kr1.33B | -2.68 | -99.58% | ― | -87.22% | -70.29% | |
43 Neutral | kr355.23M | -3.13 | -18.05% | ― | ― | 15.97% |
* Healthcare Sector Average
SE:CANTA
Cantargia AB
1.38
-1.66
-54.47%
SE:BINV
BioInvent International AB
20.25
-8.05
-28.45%
SE:ONCO
Oncopeptides AB
1.69
-3.24
-65.75%
SE:ISOFOL
Isofol Medical AB
1.14
0.44
64.40%
SE:ELIC
Elicera Therapeutics AB
2.80
-3.05
-52.10%
SE:IMMU
Immunicum AB
5.60
-1.09
-16.29%
Cantargia AB Corporate Events
Cantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer
Sep 30, 2026
Cantargia AB has reported new preclinical data presented at an AACR pancreatic cancer conference showing that its antibody nadunolimab, when combined with a RAS inhibitor, acts on distinct aspects of pancreatic ductal adenocarcinoma biology and re...
Cantargia Ramps Up Investor Outreach with Series of September Conferences
Aug 28, 2026
Cantargia AB will engage with the investment community at several high-profile conferences in September 2026, including the H.C. Wainwright Global Investment Conference in New York, the Biostock Investing in Life Sciences event in Stockholm, and t...
Cantargia details pipeline and financials in H1 2026 interim report
Aug 19, 2026
Cantargia AB has released its interim report for January to June 2026, offering a translated version for non‑Swedish investors while maintaining the Swedish original as the prevailing document. The report outlines the company’s pipelin...
Cantargia schedules Q2 2026 results release and investor conference call
Aug 4, 2026
Cantargia will publish its interim report for January to June 2026 on August 19 and host a quarterly conference call that afternoon for investors, analysts and media, led by CEO Hilde Steineger and CFO Patrik Renblad. Management plans to review th...
Cantargia Expands Share Capital After Rights Issue Completion
Jul 31, 2026
Cantargia AB has expanded its share capital following the completion of a recent rights issue, increasing the number of shares and voting rights by 33,333,333. As of the last trading day of July, the company now has a total of 281,944,988 shares a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.